448 unknown. 448 Phase 1, 168 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 448 | Unknown 448 |
| Phase 2 | 168 | Unknown 168 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose, LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose, Placebo Comparator: Placebo - Leprosy | Phase 1 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 54 | 2025-01-02 | 2024-10-04 |
| Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis Imatinib, Compound sodium lactate solution - Sepsis, Fluid Overload | Phase 1 / Phase 2 | Unknown | Belfast Health and Social Care Trust | 65 | 2024-12-01 | 2024-10-04 |
| Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 Group 1 drug, Group 2: Drug and placebo, Group 3: Drug and palcebo - Ocular Surface Symptom, Ocular Surface Disease | Phase 1 | Unknown | Mohsen Pourazizi | 150 | 2024-10-30 | 2024-10-03 |
| Studying Topiramate for Re-Activating the HIV-1 Reservoir Topiramate - HIV-1-infection, Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 12 | 2024-09-01 | 2024-02-28 |
| CelAgace™ OraRinse Solution for Treatment of Candidiasis silver citrate complex and acemannan - Candidiasis, Oral | Phase 1 / Phase 2 | Unknown | CelaCare Technologies, Inc. | 15 | 2024-09-01 | 2024-02-09 |
| Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia TP-122A - Pneumonia, Ventilator-Associated | Phase 1 / Phase 2 | Unknown | Technophage, SA | 15 | 2024-09-01 | 2024-04-17 |
| A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers ZY19489 + Ferroquine (FQ), Placebo - Uncomplicated Malaria, Asymptomatic Condition | Phase 1 | Unknown | Zydus Lifesciences Limited | 36 | 2024-08-30 | 2024-10-01 |
| Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma TS-2021 - Glioblastoma Multiforme, Glioma, Malignant | Phase 1 | Unknown | Beijing Neurosurgical Institute | 30 | 2024-08-29 | 2024-10-31 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years Placebo, 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha) - HPV Infection, HPV-Related Carcinoma | Phase 1 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 72 | 2024-08-03 | 2025-01-06 |
| Study of the Drug B11-FC (Botulism Treatment) B11-FC, Botulinum neurotoxin type A, Placebo - Botulism | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 40 | 2024-08-01 | 2024-08-30 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection BSG005 - Invasive Fungal Infection | Phase 1 / Phase 2 | Unknown | Biosergen AS | 15 | 2024-07-01 | 2025-04-06 |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT) - Pleurisy | Phase 1 | Unknown | Healthgen Biotechnology Corp. | 72 | 2024-07-01 | 2024-07-29 |
| A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B TQA3038 injection/placebo, Nucleotide drugs Control group - Hepatitis B, Chronic | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 162 | 2024-06-01 | 2024-06-11 |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults STR-V003/Placebo - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Unknown | Starna Therapeutics | 48 | 2024-05-01 | 2024-04-03 |
| A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage - Hiv | Phase 1 | Unknown | International AIDS Vaccine Initiative | 8 | 2024-04-16 | 2024-06-11 |
| Optimizing Reversal of HIV Latency With Combination Therapy Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 49 | 2024-04-01 | 2024-02-05 |
| A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult GR2102 injection, placebo - Respiratory Syncytial Virus Infections | Phase 1 | Unknown | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 132 | 2024-03-23 | 2024-08-22 |
| Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT Virus -specific T cells - Viral Infection After HSCT | Phase 1 | Unknown | Istituto Giannina Gaslini | 10 | 2024-02-27 | 2024-03-06 |
| Effect of Quercetin in Treatment of Periodontitis Quercetin, scaling and root planing - Inflammation Gum | Phase 1 | Unknown | Assiut University | 20 | 2024-02-20 | 2024-01-31 |
Showing 20 of 448. Sign in to see all of them.
COVID-19 (136) · Burkitt Lymphoma (43) · HIV Infections (30) · Acquired Immunodeficiency Syndrome (23) · Coronavirus Infections (22) · Hepatitis B, Chronic (14) · Lymphoma (14) · Influenza, Human (13) · Pneumonia (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Malaria (12) · Lymphoma, B-Cell (11) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Non-Hodgkin (11)
Virus Diseases (319) · RNA Virus Infections (235) · Respiratory Tract Diseases (180) · Respiratory Tract Infections (171) · Lung Diseases (160) · Coronaviridae Infections (149) · Nidovirales Infections (149) · Pneumonia, Viral (138) · Pneumonia (137) · Coronavirus Infections (127) · Immune System Diseases (93) · DNA Virus Infections (89) · Pathological Conditions, Signs and Symptoms (89) · Pathologic Processes (82)
Cyclophosphamide (11) · Saline Solution (11) · fludarabine (8) · Injections (5) · BNT162 Vaccine (4) · Cytarabine (4) · Etoposide (4) · Sodium Chloride (4) · Standard of Care (4) · tocilizumab (4) · Azithromycin (3) · Filgrastim (3) · Hydroxychloroquine (3) · Indium (3) · Influenza Vaccines (3)
Beijing 302 Hospital (7) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (7) · University of Oxford (7) · African Malaria Network Trust (5) · International AIDS Vaccine Initiative (5) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (4) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (4) · Hadassah Medical Organization (4) · Shenzhen BinDeBio Ltd. (4) · Wuhan BravoVax Co., Ltd. (4) · Assiut University (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Cytheris SA (3) · D'Or Institute for Research and Education (3) · HK inno.N Corporation (3)
China (100) · United States (75) · Brazil (18) · Canada (18) · South Korea (14) · Australia (13) · France (10) · Russia (10) · United Kingdom (10) · Israel (9) · Mexico (8) · Egypt (7) · Iran (6) · Netherlands (6) · Mali (5)
Nicholas Paton (3) · Peter Kremsner, MD, PhD (3) · Gerald L. DeNardo, MD (2) · Ivan Fan-ngai Hung (2) · Junqi Niu, PHD (2) · Ke Xu, Ph.D (2) · Kurt Barnhart, MD (2) · Lanjuan Li (2) · Lin Yuan (2) · Lucia Silla, MD, PhD (2) · Moneeb Ashraf, MBBS (2) · Muhammad Ashraf, PhD (2) · Shoaib Ashraf, PhD (2) · Sohaib Ashraf, MBBS (2)
PMID 34473343, PMID 31986264, PMID 32257537, PMID 10048682, PMID 10051178, PMID 10415784, PMID 10632319, PMID 10655111, PMID 10669330, PMID 11023960, PMID 11807307, PMID 11815760, PMID 11886437, PMID 11955556, PMID 12563677, PMID 12672715, PMID 1406879, PMID 14719037, PMID 14757603, PMID 14765348, PMID 15456731, PMID 15530127, PMID 1559306, PMID 15642810, PMID 15663512, PMID 15880120, PMID 16257309, PMID 16787239, PMID 17015575, PMID 17181919, PMID 1731020, PMID 17548546, PMID 17651080, PMID 17662768, PMID 17686878, PMID 18097874, PMID 18369153, PMID 18419347, PMID 18552864, PMID 18595987, PMID 19056593, PMID 19105791, PMID 19134433, PMID 19397687, PMID 19453649, PMID 19607731, PMID 19855847, PMID 19998041, PMID 20084502, PMID 20094812
2009 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), P01AI047490 (1), P30CA060553 (1), R43AI052634 (1), R44HD057744 (1), UM1AI126620 (1)